🇺🇸 FDA
Patent

US 11649239

Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)

granted A61PA61P25/16A61P35/00

Quick answer

US patent 11649239 (Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)) held by Medshine Discovery Inc. expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medshine Discovery Inc.
Grant date
Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P25/16, A61P35/00